1 | Cancer | 2.99% | |
2 | Results | 2.99% | |
3 | Patients | 2.99% | |
4 | ASCO | 2.99% | |
5 | Phase | 2.99% | |
6 | Urothelial | 1.49% | |
7 | Clinical | 1.49% | |
8 | Clinically | 1.49% | |
9 | Neoadjuvant | 1.49% | |
10 | Study | 1.49% | |
11 | Rapid | 1.49% | |
12 | Reviewed | 1.49% | |
13 | Sugar | 1.49% | |
14 | Natural | 1.49% | |
15 | Advanced | 1.49% | |
16 | New | 1.49% | |
17 | Molecular | 1.49% | |
18 | Effusion-Synovitis | 1.49% | |
19 | Osteoarthritis | 1.49% | |
20 | Czechia | 1.49% | |
21 | Have | 1.49% | |
22 | Cisplatin-Ineligible | 1.49% | |
23 | (BT8009) | 1.49% | |
24 | Nectin-4?targeting | 1.49% | |
25 | Pevedotin | 1.49% | |
26 | Metastatic | 1.49% | |
27 | Balance | 1.49% | |
28 | DISCERN | 1.49% | |
29 | Accurate | 1.49% | |
30 | Deficient | 1.49% | |
31 | Men | 1.49% | |
32 | Duravelo-1 | 1.49% | |
33 | Niraparib | 1.49% | |
34 | IARC-coordinated | 1.49% | |
35 | Zelenectide | 1.49% | |
36 | Not | 1.49% | |
37 | Ultrasound | 1.49% | |
38 | Seen | 1.49% | |
39 | Effect | 1.49% | |
40 | GlucoPure | 1.49% | |
41 | Gene | 1.49% | |
42 | Pembrolizumab | 1.49% | |
43 | Blood | 1.49% | |
44 | Locally | 1.49% | |
45 | Point-of-Care | 1.49% | |
46 | Untreated | 1.49% | |
47 | Previously | 1.49% | |
48 | Localized | 1.49% | |
49 | Prostate | 1.49% | |
50 | Preliminary | 1.49% | |
는 분류, 데이터 기준으로 의 기사에서 의 고유명사 데이터를 통해 생성되었습니다.
|